The potential effects on fetal development and the unknown presence in breast milk make these peptides inappropriate for use during pregnancy or breastfeeding
Nevertheless, dysregulation of HIF-1 signaling axis would lead to skeletal dysplasia by interfering with cellular bioenergetics and biosynthesis (Stegen et al., 2019)
GHK-Cu is not FDA-approved for any human use, and the injectable/systemic route in particular has not been evaluated or authorized
Enhanced deposition of extracellular matrix and activation of cancer-associated fibroblasts build tangible physical barriers to molecular transport [13]
According to the policy statement of the ACMG on clinical sequencing (Green et al., 2013), it is of utmost importance to alert the patient to the possibility of such results in pretest patient discussions, clinical testing, and reporting of resultssecondary findings list most recently updated to version 3.3 (Lee K
But what about GHK-Cus side effects
